Erratum: Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence (Cell Death and Disease (2014) 5 (e1089) DOI: 10.1038/cddis.2014.63);Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  Gitenay, D ^a,b,c   Wiel, C ^a,b,c   Lallet Daher, H ^a,b,c   Vindrieux, D ^a,b,c   Aubert, S ^d,e   Payen, L ^a,b,c,f   Simonnet, H ^a,b,c   Bernard, D ^a,b,c  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIV LILLE   (France)

^e JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^f HOSPICES CIVILS DE LYON   (France)

Author keywords

glucose metabolism; metabolites; oncogene induced senescence

Indexed keywords

GLUCOSE; GLUCOSE 6 PHOSPHATE; HEXOKINASE; HEXOKINASE 2; HEXOSAMINE; PENTOSE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE;

CELL AGING; CELLS, CULTURED; ENERGY METABOLISM; ENZYME INHIBITORS; EPITHELIAL CELLS; FEMALE; GLUCOSE; GLUCOSE-6-PHOSPHATE; GLYCOLYSIS; HEXOKINASE; HEXOSAMINES; HUMANS; KINETICS; MAMMARY GLANDS, HUMAN; ONCOGENES; PENTOSE PHOSPHATE PATHWAY; TIME FACTORS; TRANSFECTION;

EID: 84896797170     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.360     Document Type: Erratum

References (43)

1. Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012; 149: 49-62.
2. Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
3. Blanchet E, Annicotte JS, Lagarrigue S, Aguilar V, Clape C, Chavey C et al. E2F transcription factor-1 regulates oxidative metabolism. Nat Cell Biol 2011; 13: 1146-1152.
4. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev 2009; 23: 537-548.
5. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65: 177-185.
6. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: Identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001; 276: 43407-43412.
7. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S et al. Phosphate-Activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010; 107: 7461-7466.
8. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007; 27: 7381-7393.
9. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-1344.
10. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL et al. Emerging metabolic targets in cancer therapy. Front Biosci 2011; 16: 1844-1860.
11. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: Cancer's stygian link to the 'Warburg Effect' and a pivotal target for effective therapy. Semin Cancer Biol 2009; 19: 17-24.
12. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479: 547-551.
13. Collado M, Serrano M. Senescence in tumours: Evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-57.
14. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. AMP-Activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18: 283-293.
15. Zwerschke W, Mazurek S, Stockl P, Hutter E, Eigenbrodt E, Jansen-Durr P. Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence. Biochem J 2003; 376: 403-411.
16. Jiang P, Du W, Mancuso A, Wellen KE, Yang X. Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 2013; 493: 689-693.
17. Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013; 498: 109-112.
18. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/ p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998; 396: 84-88.
19. Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H et al. A conditionally-Active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. Oncogene 2000; 19: 526-536.
20. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 1997; 17: 5598-5611.
21. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM et al. A negative feedback signaling network underlies oncogeneinduced senescence. Cancer Cell 2006; 10: 459-472.
22. Acosta JC, O'Loghlen A, Banito A, Raguz S, Gil J. Control of senescence by CXCR2 and its ligands. Cell Cycle 2008; 7: 2956-2959.
23. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M et al. Tumour biology: Senescence in premalignant tumours. Nature 2005; 436: 642.
24. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, C De Martino. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 1981; 66: 497-499.
25. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B et al. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 1981; 41: 4661-4666.
26. Wilson JE. Isozymes of mammalian hexokinase: Structure, subcellular localization and metabolic function. J Exp Biol 2003; 206: 2049-2057.
27. Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz JH et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013; 501: 421-425.
28. Riley JK, Carayannopoulos MO, Wyman AH, Chi M, Moley KH. Phosphatidylinositol 3-kinase activity is critical for glucose metabolism and embryo survival in murine blastocysts. J Biol Chem 2006; 281: 6010-6019.
29. Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011; 42: 36-49.
30. Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 2012; 26: 1055-1069.
31. Dennis JW, Lau KS, Demetriou M, Nabi IR. Adaptive regulation at the cell surface by N-glycosylation. Traffic 2009; 10: 1569-1578.
32. Love DC, Krause MW, Hanover JA. O-GlcNAc cycling: Emerging roles in development and epigenetics. Semin Cell Dev Biol 2010; 21: 646-654.
33. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 2010; 24: 2784-2799.
34. Huber AL, Lebeau J, Guillaumot P, Petrilli V, Malek M, Chilloux J et al. p58(IPK)-mediated attenuation of the proapoptotic PERK-CHOP pathway allows malignant progression upon low glucose. Mol Cell 2013; 49: 1049-1059.
35. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000; 57: 170-178.
36. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208: 313-326.
37. Braig M, Schmitt CA. Oncogene-induced senescence: Putting the brakes on tumor development. Cancer Res 2006; 66: 2881-2884.
38. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. BRAFE600-Associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-724.
39. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013; 24: 213-228.
40. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-1079.
41. Bernard D, Quatannens B, Begue A, Vandenbunder B, Abbadie C. Antiproliferative and antiapoptotic effects of crel may occur within the same cells via the up-regulation of manganese superoxide dismutase. Cancer Res 2001; 61: 2656-2664.
42. Augert A, Payre C, de Launoit Y, Gil J, Lambeau G, Bernard D. The M-Type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep 2009; 10: 271-277.
43. Yang SH, Sarkar SN, Liu R, Perez EJ, Wang X, Wen Y et al. Estrogen receptor beta as a mitochondrial vulnerability factor. J Biol Chem 2009; 284: 9540-9548.